Webinar Part 4: Results of the STAR-I Trial at 24 Months

Show Description +

The STAR-I clinical trial is reviewed and summarized by Philippe Denis, MD, PhD (France). Prof. Denis reviews the study design, initial results, safety data, and key takeaways in relation to IOP and medication reduction in the study population. Final two-year data from MINIject's STAR-I trial showed consistently positive IOP and medication reduction in patients at trial conclusion, with no safety concerns reported. Read more in the British Journal of Ophthalmology, October 2020.

Posted: 11/11/2020

Keywords:

iSTAR Medical

Up Next


Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Enhanced and Sustained IOP reduction with MINIject

Iqbal Ike K. Ahmed, MD, FRCSC, Michel Vanbrabant, Steven Vold, MD

Consider the Supraciliary Space With MINIject

Joseph F. Panarelli, MD; and I. Paul Singh, MD

Question and Answer: MINIject Supraciliary MIGS Device

Joseph F. Panarelli, MD; Leon Au, BSc, MBBS, FRCOphth; and Tim Schultz, MD, PhD, FEBO

STAR-GLOBAL 3-Year Results

I. Paul Singh, MD

Q&A: MINIject Supraciliary MIGS Device

Steven R. Sarkisian Jr, MD; Karsten Klabe, MD; Faisal Ahmed, MD; and I. Paul Singh, MD

Full Webinar: An Eye-Opening Update on MIGS

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

European STAR-II Trial Results at One Year

Julián García-Feijoó, MD, PhD

Webinar Part 1: Where Do We Stand With MIGS?

Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD, Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Webinar Part 4: Results of the STAR-I Trial at 24 Months

The STAR-I clinical trial is reviewed and summarized by Philippe Denis, MD, PhD (France). Prof. Denis reviews the study design, initial results, safety data, and key takeaways in relation to IOP and medication reduction in the study population. Final two-year data from MINIject's STAR-I trial showed consistently positive IOP and medication reduction in patients at trial conclusion, with no safety concerns reported. Read more in the British Journal of Ophthalmology, October 2020.

Posted: 11/11/2020

Keywords:

iSTAR Medical

About iSTAR Medical

Visit us online: istarmed.com

Follow iSTAR Medical